Gene Editing's Hardest Problem Isn't Biology Anymore Either

CRISPR-based gene editing has moved from theoretical promise to clinical reality faster than almost anyone predicted a decade ago — therapies correcting the underlying genetic cause of specific diseases now exist and work. The remaining obstacle for most patients isn't whether the science works. It's that a personalized, one-time genetic cure currently costs an amount that puts it out of reach for the overwhelming majority of people who could benefit.

This is a familiar pattern in the history of medicine: the first version of a breakthrough therapy is almost always expensive, artisanal, and narrow in reach, and the real work of the following decade is turning that first version into something that can be manufactured and delivered at a cost health systems can actually sustain.

The organizations that matter most in gene editing's next phase may not be the labs pushing the scientific frontier further — it's the ones solving manufacturing cost curves, the unglamorous work that turns a proof of concept into something resembling universal access.